Empirical antibiotic monotherapy for febrile neutropenia: Systematic review and meta-analysis of randomized controlled trials

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 2, 2006, Pages 176-189

  Paul, Mical ^a,b   Yahav, Dafna ^a   Fraser, Abigail ^a   Leibovici, Leonard ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

; lactams; Carbapenems; Cefepime; Ceftazidime; Piperacillin tazobactam

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN; CILASTATIN PLUS IMIPENEM; IMIPENEM; MEROPENEM; NEW DRUG; PENICILLIN DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; POLYPEPTIDE ANTIBIOTIC AGENT; SULPERAZON; TIMENTIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; CLINICAL TRIAL; COCHRANE LIBRARY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG APPROVAL; DRUG CHOICE; DRUG USE; EMBASE; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; HUMAN; INFECTION; MEDLINE; META ANALYSIS; MONOTHERAPY; MORTALITY; OUTCOME ASSESSMENT; PSEUDOMEMBRANOUS COLITIS; PUBLICATION; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; REGISTER; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CARBAPENEMS; CEPHALOSPORINS; ENZYME INHIBITORS; FEVER; HUMANS; NEUTROPENIA; PENICILLANIC ACID; PENICILLINS; QUALITY ASSURANCE, HEALTH CARE; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 31544456662     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki448     Document Type: Review

References (57)

1. Bodey GP, Elting L, Kassamali H et al. Escherichia coli bacteremia in cancer patients. Am J Med 1986; 81: 85-95.
2. Paul M, Soares-Weiser K, Leibovici L. β-Lactam monotherapy versus β-lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. Br Med J 2003; 326: 1111-15.
3. Hughes WT, Armstrong D, Bodey GP et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-51.
4. Fritsche TR, Sader HS, Jones RN. Comparative activity and spectrum of broad-spectrum β-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) tested against 12,295 staphylococci and streptococci: Report from the SENTRY antimicrobial surveillance program (North America: 2001-2002). Diagn Microbiol Infect Dis 2003; 47: 435-40.
5. Pfaller MA, Jones RN, Marshall SA et al. Inducible amp C β-lactamase producing gram-negative bacilli from bloodstream infections: Frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE). Diagn Microbiol Infect Dis 1997; 28: 211-19.
6. Jacoby GA, Munoz-Price LS. The new β-lactamases. N Engl J Med 2005; 352: 380-91.
7. Alderson P, Green S, Higgins JPT et al. Highly sensitive search strategies for identifying reports of randomized controlled trials in MEDLINE. Cochrane Reviewers' Handbook 4.2.2 [updated December 2003]. Appendix & Sons, Ltd; 5b. In: The Cochrane Library, Issue 1. Chichester, UK: John Wiley & Sons, Ltd.; 2004.
8. Moher D, Pham B, Jones A et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352: 609-13.
9. Schulz KF, Chalmers I, Hayes RJ et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-12.
10. Higgins JP, Thompson SG, Deeks JJ et al. Measuring inconsistency in meta-analyses. Br Med J 2003; 327: 557-60.
11. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: Power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000; 53: 1119-29.
12. Paul M, Yahav D, Fraser A et al. Single-agent antibiotic therapy for the initial, empirical, treatment of febrile neutropenia: Comparison of β-lactams. (Protocol). The Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No.: CD005197. doi: 10.1002/14651858.CD005197.
13. Anaissie EJ, Fainstein V, Bodey GP et al. Randomized trial of β-lactam regimens in febrile neutropenic cancer patients. Am J Med 1988; 84: 581-9.
14. Aoun M, Boogaerts MA, Bosly AJ et al. A multicenter, randomized, prospective, comparative study of cefepime plus vancomycin versus ceftazidime plus vancomycin as empiric therapy in the treatment of febrile episodes in granulocytopenic patients with hematological malignancies. Joint clinical/statistical review of NDA 50,679/SE1-002. http://www.fda.gov/cder/foi/nda/97/050679s002.htm (18 September 2005, date last accessed).
15. Aparicio J, Oltra A, Llorca C et al. Randomised comparison of ceftazidime and imipenem as initial monotherapy for febrile episodes in neutropenic cancer patients. Eur J Cancer 1996; 32A: 1739-43.
16. Bickers J, Gumbart C, Cavalier J et al. A prospective randomized trial of cefoperazone plus sulbactam versus imipenem-cilastatin in febrile neutropenic patients. Clin Res 1990; 38: 991A.
17. Biron P, Fuhrmann C, Cure H et al. Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer). J Antimicrob Chemother 1998; 42: 511-18.
18. Bodey GP, Fainstein V, Elting LS et al. β-Lactam regimens for the febrile neutropenic patient. Cancer 1990; 65: 9-16.
19. Bodey G, Abi-Said D, Rolston K et al. Imipenem or cefoperazone-sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients. Eur J Clin Microbiol Infect Dis 1996; 15: 625-34.
20. Bohme A, Shah PM, Stille W et al. Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: A prospective randomized pilot study. Eur J Med Res 1998; 3: 324-30.
21. Boogaerts MA, Demuynck H, Mestdagh N et al. Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. J Antimicrob Chemother 1995; 36: 185-200.
22. Bow EJ, Noskin GA, Schwarer AP et al. Efficacy of piperacillin/ tazobactam as initial empiric therapy of febrile neutropenia in patients with hematologic malignancy. In: Abstracts of the Forty-fifth Annual Meeting of the American Society of Hematology, San Diego, CA, 2003. Abstract 1000. American Society of Hematology, Washington, DC, USA.
23. Bow EJ, Schwarer AP, Laverdiere M et al. Efficacy of piperacillin/ tazobactam as initial empiric therapy of febrile neutropenia in patients with hematologic malignancy. In: Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Abstract L-114. American Society for Microbiology, Washington, DC, USA.
24. Noskin GA, Vesole D, Szer J et al. Multicenter efficacy and safety study of piperacillin/tazobactam as empiric treatment for neutropenic fever in patients with hematologic malignancies. In: Abstracts of the Annual Meeting of the Infectious Diseases Society of America, San Diego, CA, 2003. Abstract no. 373. Infectious Diseases Society of America, Alexandria, VA, USA.
25. Chandrasekar PH, Arnow PM. Cefepime versus ceftazidime as empiric therapy for fever in neutropenic patients with cancer. Ann Pharmacother 2000; 34: 989-95.
26. Cherif H, Bjorkholm M, Engervall P et al. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies. Scand J Infect Dis 2004; 36: 593-600.
27. Chuang YY, Hung IJ, Yang CP et al. Cefepime versus ceftazidime as empiric monotherapy for fever and neutropenia in children with cancer. Pediatr Infect Dis J 2002; 21: 203-9.
28. Cornely OA, Reichert D, Buchheidt D et al. Three-armed multicenter randomized study on the empiric treatment of neutropenic fever in a high risk patient population (PEG Study III). In: Abstracts of the Forty-first Interscience Conference on Antimicrobials Agents and Chemotherapy, Chicago, IL, 2001. Abstract L-775, p. 446. American Society for Microbiology, Washington, DC, USA.
29. Feld R, DePauw B, Berman S et al. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: A randomized, double-blind trial. J Clin Oncol 2000; 18: 3690-8.
30. Figuera A, Rivero N, Pajuelo F et al. Initial empiric therapy of febrile neutropenia with antibiotic monotherapy. Piperacillin/tazobactam versus imipenem/cilastatin (1994-1996). Med Clin 2001; 116: 610-11.
31. Fleischhack G, Hartmann C, Simon A et al. Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer. J Antimicrob Chemother 2001; 47: 841-53.
32. Freifeld AG, Walsh T, Marshall D et al. Monotherapy for fever and neutropenia in cancer patients: A randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995; 13: 165-76.
33. Glauser M, Dekker AW, Van Marwijkkooy M et al. A multicenter comparative study of cefepime vs. ceftazidime as empiric therapy in the treatment of febrile episodes in neutropenic patients. Joint clinical/statistical review of NDA 50,679/SE1-002. http://www.fda.gov/cder/foi/nda/97/ 050679s002.htm (18 September, 2005, date last accessed).
34. Kebudi R, Gorgun O, Ayan I et al. Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors. Med Pediatr Oncol 2001; 36: 434-41.
35. Kutluk T, Kurne O, Akyuz C et al. Cefepime vs. meropenem as empirical therapy for neutropenic fever in children with lymphoma and solid tumours. Pediatr Blood Cancer 2004; 42: 284-6.
36. Liang R, Yung R, Chiu E et al. Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients. Antimicrob Agents Chemother 1990; 34: 1336-41.
37. Lindblad R, Rodjer S, Adriansson M et al. Empiric monotherapy for febrile neutropenia - a randomized study comparing meropenem with ceftazidime. Scand J Infect Dis 1998; 30: 237-43.
38. Mustafa MM, Carlson L, Tkaczewski I et al. Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J 2001; 20: 362-9.
39. Oppenheim BA, Morgenstern GR, Chang J et al. Safety and efficacy of piperacillin/tazobactam versus meropenem in the treatment of febrile neutropenia. J Infect 2001; 43: A67.
40. Raad, II, Escalante C, Hachem RY et al. Treatment of febrile neutropenic patients with cancer who require hospitalization: A prospective randomized study comparing imipenem and cefepime. Cancer 2003; 98: 1039-47.
41. Ramphal R, Haddow A, McCracken GH. A comparative study of cefepime vs. ceftazidime in the treatment of adult cancer patients with fever and neutropenia. Joint clinical/statistical review of NDA 50,679/SE1-002. http://www.fda.gov/cder/foi/nda/97/050679s002.htm (18 September, 2005, date last accessed).
42. Rolston KV, Berkey P, Bodey GP et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 1992; 152: 283-91.
43. Shichmanter R, Miller E, Shtalrid M et al. Empiric antibiotic treatment of adults with neutropenic fever in a general internal medicine ward. In: Abstracts of the Fourteenth European Congress of Clinical Microbiology and Infectious Diseases, Prague, 2004. Abstract P1452. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
44. Tamura K, Matsuoka H, Tsukada J et al. Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: comparative study. Am J Hematol 2002; 71: 248-55.
45. Vandercam B, Gerain J, Humblet Y et al. Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic cancer patients. Ann Hematol 2000; 79: 152-7.
46. Wang FD, Liu CY, Hsu HC et al. A comparative study of cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients. Chemotherapy 1999; 45: 370-9.
47. Winston DJ, Bartoni K, Bruckner DA et al. Randomized comparison of sulbactam/cefoperazone with imipenem as empirical monotherapy for febrile granulocytopenic patients. Clin Infect Dis 1998; 26: 576-83.
48. Hess U, Bohme C, Rey K et al. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients. Support Care Cancer 1998; 6: 402-9.
49. Juni P, Nartey L, Reichenbach S et al. Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis. Lancet 2004; 364: 2021-9.
50. Psaty BM, Furberg CD. COX-2 inhibitors - lessons in drug safety. N Engl J Med 2005; 352: 1133-5.
51. Sanders CC. Cefepime: The next generation? Clin Infect Dis 1993; 17: 369-79.
52. Goldstein FW. Cephalosporinase induction and cephalosporin resistance: A longstanding misinterpretation. Clin Microbiol Infect 2002; 8: 823-5.
53. Egger M, Altman DG, Smith GD. Systematic Reviews in Health Care: Meta-Analysis in Context. London: BMJ Books; 2001.
54. Klastersky J, Paesmans M, Rubenstein EB et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18: 3038-51.
55. Ortega M, Rovira M, Filella X et al. Prospective evaluation of procalcitonin in adults with febrile neutropenia after haematopoietic stem cell transplantation. Br J Haematol 2004; 126: 372-6.
56. Reuter S, Kern WV, Sigge A et al. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis 2005; 40: 1087-93.
57. Paul M, Borok S, Fraser A et al. Empirical antibiotics against Gram-positive infections for febrile neutropenia: Systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2005; 55: 436-44.